Dr. Reddy’s launches new drug for acid peptic disease; check details

Tegoprazan is a next-generation potassium-competitive acid blocker (PCAB) designed to treat acid peptic diseases (APD), including erosive gastro-oesophageal reflux disease (GERD), non-erosive gastro-oesophageal reflux disease (NERD), and gastric ulcers. According to the company, the drug offers a rapid onset of action and sustains elevated gastric pH levels for an extended period, potentially providing significant clinical benefits in the effective management of APD.

The drugmaker stated that Tegoprazan is already approved in 21 countries, including South Korea and China, and is undergoing registration in several others. The company also noted that the molecule has successfully completed a Phase III trial in the United States, as mentioned in their press release.

The launch follows an exclusive partnership formed in 2022 between Dr. Reddy’s and South Korea-based HK inno.N Corporation to commercialise Tegoprazan in India and select emerging markets.

On Tuesday, shares of Dr Reddy's Laboratories Ltd settled 0.79% higher at ₹1,311.10 apiece on the National Stock Exchange (NSE). The announcement, however, came post market hours.

In the last five trading sessions, shares of Dr Reddy's Laboratories rose 1.14%, while on a monthly basis it showed 3.83% uptick. The scrip advanced 13.86% in a six month period.

The stock touched its 52 week high of ₹1,405.90 on January 8, 2025 and its 52 week low of ₹1,020.00 on April 7, 2025. The company’s market capitalisation is currently at ₹1,09,425.36 crore.

Commenting on the development, M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy's said, "We are happy to launch Tegoprazan (PCAB®) in India, reinforcing our commitment to innovation in gastrointestinal diseases treatment – a key focus area for us. Our partnership with HK inno.N Corporation for Tegoprazan brings together complementary strengths to enhance patient access to an innovative molecule that addresses critical gaps in acid peptic disease management and improves outcomes."

HK inno.N Corporation CEO Dal-Won Kwak stated that with the launch of Tegoprazan in India, the company aims to establish it as a leading innovative therapy in the potassium-competitive acid blocker (PCAB) class, providing a valuable new treatment option to enhance gastrointestinal care in the country.